Antiviral drugs

Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement

Retrieved on: 
Thursday, April 1, 2021
Antiviral drugs, Sarbecovirus, Medical specialties, Arbutus Biopharma, Medicine, ABUS, Virology, Mpro, Coronavirus, Coronavir, Severe acute respiratory syndrome, 3C-like protease

and MUNICH, Germany, April 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ: ABUS), X-Chem, Inc. (X-Chem) and Proteros biostructures GmbH (Proteros) announced today that they have entered into a discovery research and license agreement focused on the discovery of novel inhibitors targeting the SARS-CoV-2 nsp5 main protease (Mpro).

Key Points: 
  • and MUNICH, Germany, April 01, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (NASDAQ: ABUS), X-Chem, Inc. (X-Chem) and Proteros biostructures GmbH (Proteros) announced today that they have entered into a discovery research and license agreement focused on the discovery of novel inhibitors targeting the SARS-CoV-2 nsp5 main protease (Mpro).
  • The agreement is designed to accelerate the development of pan-coronavirus agents to treat COVID-19 and potential future coronavirus outbreaks.
  • We are exhilarated to join forces with industry leaders Arbutus and Proteros in this effort and bring our drug discovery expertise to this important area of antiviral research.
  • Arbutus is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection.

Concerted Efforts for Effective Management of Chronic Viral Diseases spells Growth in Antiviral Combination Therapies Market, Efficacy of Antiviral Combination Drugs unfolds Demand, TMR

Retrieved on: 
Wednesday, March 31, 2021
Biocides, Antiviral drugs, Nucleosides, Drug discovery, Biology, Toxicology, Medical specialties

Meanwhile, the efficacy of combination antiviral drugs for managing chronic hepatitis B is in the nascent stages.

Key Points: 
  • Meanwhile, the efficacy of combination antiviral drugs for managing chronic hepatitis B is in the nascent stages.
  • Efforts to explore combining antiviral combination drugs with traditional Chinese medicine is creating opportunities in the antiviral combination therapies market.
  • Considerable evidence of efficacy of combination antiviral therapies in the treatment of chronic viral diseases fuels the antiviral combination therapies market.
  • The promising potential of certain antiviral drugs in a triple combination in the treatment of COVID-19 spawns new opportunities in the antiviral combination therapies market.

Concerted Efforts for Effective Management of Chronic Viral Diseases spells Growth in Antiviral Combination Therapies Market, Efficacy of Antiviral Combination Drugs unfolds Demand, TMR

Retrieved on: 
Tuesday, April 19, 2022
Biocides, Antiviral drugs, Nucleosides, Drug discovery, Biology, Toxicology, Medical specialties

Meanwhile, the efficacy of combination antiviral drugs for managing chronic hepatitis B is in the nascent stages.

Key Points: 
  • Meanwhile, the efficacy of combination antiviral drugs for managing chronic hepatitis B is in the nascent stages.
  • Efforts to explore combining antiviral combination drugs with traditional Chinese medicine is creating opportunities in the antiviral combination therapies market.
  • Considerable evidence of efficacy of combination antiviral therapies in the treatment of chronic viral diseases fuels the antiviral combination therapies market.
  • The promising potential of certain antiviral drugs in a triple combination in the treatment of COVID-19 spawns new opportunities in the antiviral combination therapies market.

Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19

Retrieved on: 
Monday, March 29, 2021
Medical specialties, Medicine, Health, Antiviral drugs, COVID-19 drug development, Monoclonal antibodies, Bamlanivimab, Treatment and management of COVID-19, COVID-19, Food and Drug Administration

These virology data support our belief that bamlanivimab and VIR-7831 together could be a promising option for COVID-19 treatment.

Key Points: 
  • These virology data support our belief that bamlanivimab and VIR-7831 together could be a promising option for COVID-19 treatment.
  • VIR-7831 demonstrated positive results in the COMET-ICE trial and recent pre-clinical data suggest that VIR-7831 maintains activity against current circulating variants of concern.
  • We look forward to continuing conversations with the FDA about VIR-7831 as monotherapy and co-administered with bamlanivimab.
  • VIR-7831 is an investigational compound, not approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority.

EMA issues advice on the use of Celltrion’s anti-COVID-19 monoclonal antibody treatment regdanvimab (CT-P59) for COVID-19 patients in the European Union

Retrieved on: 
Friday, March 26, 2021
Infectious diseases, Biotechnology, Pharmaceutical, Health, Medical specialties, Medicine, Clinical medicine, Immunology, Monoclonal antibodies, Biotechnology, Antiviral drugs, COVID-19 drug development, Antibody, COVID-19, Celltrion Healthcare, CT-P59 (regdanvimab)

Todays CHMP positive scientific opinion by the EMA takes us a significant step closer to providing a safe and effective monoclonal antibody treatment against COVID-19 worldwide.

Key Points: 
  • Todays CHMP positive scientific opinion by the EMA takes us a significant step closer to providing a safe and effective monoclonal antibody treatment against COVID-19 worldwide.
  • We will also continue to work in close collaboration with the EMA to complete the rolling review and marketing authorisation process.
  • They also added that cocktail therapy of CT-P59 with another monoclonal antibody candidate demonstrated neutralising capability against the UK (B.1.1.7) and South African (B.1.351) variants.
  • The antibody treatment candidate would be most useful within 3-5 days of testing positive for the virus.

Istari Oncology Announces Publication of Data Showing the Investigational Immunotherapy PVSRIPO Leads to Robust, Functional T Cells—Critical for Antitumor Immunity

Retrieved on: 
Thursday, March 25, 2021
Biotechnology, Health, Science, Research, Oncology, Medical specialties, Branches of biology, Clinical medicine, Immunology, Immune system, Antiviral drugs, Cytokines, Receptors, Cancer immunology, Interferon, Immunotherapy, Vaccine, PVSRIPO, Istari Oncology

PVSRIPO is genetically engineered to elicit potent, sustained innate antiviral inflammatory patterns, which yield vigorous CD8+ T cell responses in the TME, without significant toxicity.

Key Points: 
  • PVSRIPO is genetically engineered to elicit potent, sustained innate antiviral inflammatory patterns, which yield vigorous CD8+ T cell responses in the TME, without significant toxicity.
  • PVSRIPOs activation of a specific pattern recognition receptor, MDA5, leads to the optimal cytokine signaturethe sustained, type-I/III IFN-dominant response that is required to achieve robust anticancer immunity.
  • For more information about Istari Oncology and their ongoing clinical trials and research in PVSRIPO, visit www.istarioncology.com .
  • PVSRIPO is an investigational immunotherapy based on the live attenuated Sabin type 1 poliovirus vaccine that has been genetically modified for safety.

Pfizer Initiates Phase 1 Study of Novel Oral Antiviral Therapeutic Agent Against SARS-CoV-2

Retrieved on: 
Tuesday, March 23, 2021
Biotechnology, Pharmaceutical, Medical Supplies, General Health, Health, Infectious diseases, Hospitals, Clinical trials, Health sciences, Medicine, Health, Antiviral drugs, COVID-19, Occupational safety and health, Public health, Zoonoses, Severe acute respiratory syndrome, COVID-19 drug repurposing research, COVID-19 drug development

Tackling the COVID-19 pandemic requires both prevention via vaccine and targeted treatment for those who contract the virus.

Key Points: 
  • Tackling the COVID-19 pandemic requires both prevention via vaccine and targeted treatment for those who contract the virus.
  • At the same time, Pfizers intravenous antiviral candidate is a potential novel treatment option for hospitalized patients.
  • The Phase 1 trial is a randomized, double-blind, sponsor-open, placebo-controlled, single- and multiple-dose escalation study in healthy adults evaluating the safety, tolerability and pharmacokinetics of PF-07321332.
  • Initiation of this study is supported by preclinical studies that demonstrated the antiviral activity of this potential first-in-class SARS-CoV-2 therapeutic designed specifically to inhibit replication of the SARS-CoV2 virus.

Cocrystal Pharma Reports 2020 Financial Results, Provides Business Update Including Antiviral Program Milestones

Retrieved on: 
Wednesday, March 17, 2021
Medicine, Medical specialties, Health, Antiviral drugs, Biocides, Virus, Coronavirus, Influenza

Completed all research obligations under the Merck exclusive worldwide license and collaboration agreement for influenza A/B antiviral compounds.

Key Points: 
  • Completed all research obligations under the Merck exclusive worldwide license and collaboration agreement for influenza A/B antiviral compounds.
  • As of mid-January 2021, Merck has assumed all responsibility for further program development.
  • Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses.
  • Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.

UK Clinical Trial Confirms SaNOtize’s Breakthrough Treatment for COVID-19

Retrieved on: 
Monday, March 15, 2021
Health, Infectious diseases, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Health sciences, Medicine, Health, Clinical research, Antiviral drugs, COVID-19 drug development, Clinical trials, Coronavirus disease, Public health, Monoclonal antibody, Placebo-controlled study, Placebo, SaNOtize, Dr Stephen Winchester MSc MB BS FRCPath, Robert Wilson

In a randomized, double-blind, placebo-controlled Phase 2 trial that evaluated 79 confirmed cases of COVID-19, SaNOtizes early treatment for COVID-19 significantly reduced the level of SARS-CoV-2, including in patients with high viral loads.

Key Points: 
  • In a randomized, double-blind, placebo-controlled Phase 2 trial that evaluated 79 confirmed cases of COVID-19, SaNOtizes early treatment for COVID-19 significantly reduced the level of SARS-CoV-2, including in patients with high viral loads.
  • There were no adverse health events recorded in the UK trial, or in over 7,000 self-administered treatments given in earlier Canadian clinical trials.
  • NONS is the only novel therapeutic treatment so far proven to reduce viral load in humans that is not a monoclonal antibody treatment.
  • The results of the UK trial corroborate the information gathered from SaNOtizes earlier Phase 2 trials in Canada and independent lab tests at Utah State Universitys Antiviral Research Institute.

PharmaEssentia Provides U.S. Regulatory Update on Ropeginterferon alfa-2b-njft for the Treatment of Polycythemia Vera (PV)

Retrieved on: 
Sunday, March 14, 2021
Research, FDA, Clinical trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Oncology, Antiviral drugs, Drugs, Orphan drugs, Health care, Peginterferon-alfa, Medical specialties, Interferon, ALFA, Ropeginterferon alfa-2b, Peginterferon alfa-2b

The rationale for the CRL was COVID-related travel restrictions, which delayed a required pre-approval inspection of the companys manufacturing facility in Taiwan.

Key Points: 
  • The rationale for the CRL was COVID-related travel restrictions, which delayed a required pre-approval inspection of the companys manufacturing facility in Taiwan.
  • We remain fully committed to introducing ropeginterferon alfa-2b-njft to the U.S. PV community.
  • Ropeginterferon alfa-2b-njft has Orphan Drug designation for the treatment of PV in the United States.
  • We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.